To this purpose, NCH644, U87 and T98G GBM cells were treated with selective BH3-mimetics, A1210477 (Mcl-1 inhibitor), WEHI-539 (Bcl-xL inhibitor), ABT199 (Bcl-2 inhibitor) in the presence or absence of Crizotinib. Here, BCL2 is linked to glioblastoma.